bioAffinity Technologies Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on noninvasive early-stage cancer detection, has announced the pricing of a public offering that is expected to raise approximately $4.8 million in gross proceeds. The offering comprises 1,921,799 shares of common stock or pre-funded warrants at a purchase price of $2.50 per share (or $2.493 per pre-funded warrant). Each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.007 per share. WallachBeth Capital, LLC is acting as the sole placement agent for the offering. The closing of the transaction is subject to customary conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250929684795) on September 29, 2025, and is solely responsible for the information contained therein.